Last reviewed · How we verify
Ad26.RSV.preF 1*10^11 vp
Ad26.RSV.preF 1*10^11 vp is a Biologic drug developed by Janssen Vaccines & Prevention B.V.. It is currently in Phase 1 development. Also known as: JNJ-64400141.
At a glance
| Generic name | Ad26.RSV.preF 1*10^11 vp |
|---|---|
| Also known as | JNJ-64400141 |
| Sponsor | Janssen Vaccines & Prevention B.V. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health (PHASE2)
- An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults (PHASE2)
- A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ad26.RSV.preF 1*10^11 vp CI brief — competitive landscape report
- Ad26.RSV.preF 1*10^11 vp updates RSS · CI watch RSS
- Janssen Vaccines & Prevention B.V. portfolio CI
Frequently asked questions about Ad26.RSV.preF 1*10^11 vp
What is Ad26.RSV.preF 1*10^11 vp?
Ad26.RSV.preF 1*10^11 vp is a Biologic drug developed by Janssen Vaccines & Prevention B.V..
Who makes Ad26.RSV.preF 1*10^11 vp?
Ad26.RSV.preF 1*10^11 vp is developed by Janssen Vaccines & Prevention B.V. (see full Janssen Vaccines & Prevention B.V. pipeline at /company/janssen-vaccines-prevention-b-v).
Is Ad26.RSV.preF 1*10^11 vp also known as anything else?
Ad26.RSV.preF 1*10^11 vp is also known as JNJ-64400141.
What development phase is Ad26.RSV.preF 1*10^11 vp in?
Ad26.RSV.preF 1*10^11 vp is in Phase 1.
Related
- Manufacturer: Janssen Vaccines & Prevention B.V. — full pipeline
- Also known as: JNJ-64400141
- Compare: Ad26.RSV.preF 1*10^11 vp vs similar drugs
- Pricing: Ad26.RSV.preF 1*10^11 vp cost, discount & access